Selank Dosage: Research Protocols, Half-Life, and Administration Routes

Selank Dosage: Research Context

This page indexes Selank dosage data drawn from preclinical protocols and the published Russian clinical trial. All figures represent doses administered to specific species by specific routes in specific research protocols. They are not recommendations for human administration. Selank is not approved by the FDA or EMA. For regulatory context, see Selank regulatory status.

The Selank dosage research record spans three decades of Russian preclinical work and one published human trial. Key variables across the literature: rodent models use intraperitoneal or subcutaneous routes; the human trial used intranasal delivery; and plasma half-life (approximately 3–5 minutes) diverges substantially from behavioral duration due to active metabolite formation.

Preclinical Dose Ranges

Rodent preclinical studies have administered Selank across a broad range:

Dose-response data from the stress-organ studies (Mukhina et al. 2020) used three dose levels — 80, 250, and 750 micrograms per kilogram — with no significant difference in intestinal morphology outcomes across the range, suggesting a broad protective window in that model.^[15]

Human Clinical Trial Protocol

The only published human clinical trial (Zozulia et al. 2008, N=62) administered Selank at 2,700 micrograms per day via intranasal route over a 14-day course.^[5] This is the sole published dose-duration data point for human administration in the peer-reviewed literature. The comparator (medazepam) used its standard clinical dosing. No dose-escalation, dose-finding, or pharmacokinetic study in humans is available in the published record. Selank was registered in Russia as a prescription nasal spray in 2009; the labeled dosing information from that registration is not available in English-language sources indexed by PubMed.

Selank Dosage for Anxiety: Evidence from Research Models

Anxiety as an outcome measure appears across the majority of the preclinical Selank literature. The human GAD trial used 2,700 micrograms per day intranasal for 14 days and produced statistically significant anxiety reduction on three validated scales.^[5] The chronic mild stress rat model (Kasian et al. 2017) used an unspecified Selank dose alongside diazepam 1 mg/kg and found the combination superior to either compound alone.^[6] The elevated plus maze, open field test, and forced swim test are the primary rodent anxiety measures across the literature; dose ranges for anxiolytic effects vary from 80 to 1,000 micrograms per kilogram intraperitoneal.

In the route-comparison study, anxiolytic effects were route-selective: intraperitoneal but not intranasal administration produced anxiolytic effects in the BALB/c mouse model at 300 micrograms per kilogram over 5 days.^[7] This suggests that CNS delivery pathway influences the anxiolytic profile, not only the dose.

Selank Half-Life and Duration of Action

Plasma half-life of intact Selank is approximately 3–5 minutes due to rapid enzymatic cleavage by circulating plasma peptidases. The Pro-Gly-Pro C-terminal extension provides substantially improved stability over the parent tuftsin (which has a plasma half-life of seconds), but Selank still undergoes rapid degradation in systemic circulation. This short plasma half-life does not correspond to the duration of observed behavioral effects in preclinical models.

The disconnect between plasma clearance and behavioral duration is explained by active metabolite formation. Selank metabolites formed in vivo have been documented to retain biological activity — demonstrated in the gastric antiulcerogenic model where Selank and its in vivo-formed metabolites together maintained gastric mucosal homeostasis.^[19] Downstream receptor kinetics and metabolite activity extend the functional duration beyond what plasma pharmacokinetics predict.

How Long Does Selank Last?

The apparent disconnect: plasma half-life is 3–5 minutes, but behavioral effects in rodent models persist well beyond plasma clearance. The proposed explanation is active metabolite formation — cleavage fragments of Selank retain biological activity at target pathways (GABAergic, enkephalinase, serotonergic), and downstream receptor state changes persist beyond the parent compound's presence in plasma.

In the human fMRI study (Panikratova et al. 2020), resting-state functional connectivity changes between the right amygdala and right temporal cortex were measured at both 5 minutes and 20 minutes post-intranasal administration — confirming CNS activity persists beyond the short plasma clearance window.^[20] In the Russian clinical trial, a 14-day treatment course produced a sustained clinical response on Hamilton Anxiety Scale across the observation period, consistent with a functional duration exceeding single-dose plasma kinetics.^[5] Specific duration-of-effect data in humans has not been published.

Intranasal vs Subcutaneous Administration in Research Protocols

Intranasal delivery is the primary route in Russian clinical trials and is mechanistically supported by direct olfactory-nerve CNS access — bypassing first-pass hepatic metabolism and delivering peptide directly to CNS via the olfactory epithelium. The clinical trial (2,700 micrograms per day, 14 days) and the fMRI study (unspecified dose) both used the intranasal route.^[5][20]

Intraperitoneal injection is the most common route in preclinical rodent studies. Subcutaneous administration has been used in some preclinical protocols. The 2016 route-comparison study in BALB/c and C57BL/6 mice at 300 micrograms per kilogram over 5 days found divergent receptor-level outcomes: intraperitoneal increased GABA-A receptor binding sites in frontal cortex by 38%; intranasal increased NMDA receptor binding instead — suggesting that route is not merely a delivery variable but a determinant of the CNS pharmacological profile.^[7] Comparative bioavailability data for intranasal versus subcutaneous or intraperitoneal routes in humans is not published.

Intranasal Bioavailability of Selank

Intranasal delivery to the CNS via the olfactory epithelium bypasses first-pass hepatic metabolism. The olfactory route provides direct access to the CNS via the olfactory nerve and olfactory bulb, circumventing the blood-brain barrier for a fraction of the administered dose. Published bioavailability percentages for intranasal Selank in humans are not available in the indexed literature. CNS penetration is inferred from behavioral outcomes in preclinical models, the fMRI functional connectivity data in healthy humans,^[20] and the EEG and clinical response data from the Russian clinical trial. The absence of human pharmacokinetic data (Cmax, Tmax, bioavailability fraction) is a gap in the published record.

Selank Administration Frequency in Research Models

Daily administration for 5–14 day courses characterizes the published protocol literature. The human GAD trial ran 14 consecutive days at 2,700 micrograms per day.^[5] The mouse route-comparison study ran 5 consecutive days.^[7] The restraint-stress studies administered Selank 15 minutes before each daily stress session across multi-week observation periods.^[15][16] Chronic daily use data beyond 14 days in humans is limited to the absence of adverse event reports in the single published trial — systematic long-term safety or efficacy data for multi-month human use is not available in the published record.

Selank Onset: How Quickly Does It Take Effect?

Intranasal administration reaches the CNS via the olfactory pathway rapidly. In the fMRI study in 52 healthy humans, functional connectivity changes between the right amygdala and right temporal cortex were measurable at the first scan point — 5 minutes post-administration — and persisted to the 20-minute timepoint.^[20] This is direct human neuroimaging evidence of CNS activity within minutes of intranasal dosing. In rodent models, behavioral effects on elevated plus maze and open field tests appear within the first hour post-dose across the literature. The Russian clinical trial used a multi-day course design; per-session onset data was not reported separately from the cumulative 14-day outcome.